EP4444319A4 - Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen - Google Patents

Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen

Info

Publication number
EP4444319A4
EP4444319A4 EP22903713.0A EP22903713A EP4444319A4 EP 4444319 A4 EP4444319 A4 EP 4444319A4 EP 22903713 A EP22903713 A EP 22903713A EP 4444319 A4 EP4444319 A4 EP 4444319A4
Authority
EP
European Patent Office
Prior art keywords
lactat
intaker
prevention
transport
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22903713.0A
Other languages
English (en)
French (fr)
Other versions
EP4444319A1 (de
Inventor
Uttkarsh Ayyangar
Srikala Raghavan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute For Stem Cell Science And Regenerative Medicine Instem
Inst For Stem Cell Science And Regenerative Medicine Instem
Original Assignee
Institute For Stem Cell Science And Regenerative Medicine Instem
Inst For Stem Cell Science And Regenerative Medicine Instem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Stem Cell Science And Regenerative Medicine Instem, Inst For Stem Cell Science And Regenerative Medicine Instem filed Critical Institute For Stem Cell Science And Regenerative Medicine Instem
Publication of EP4444319A1 publication Critical patent/EP4444319A1/de
Publication of EP4444319A4 publication Critical patent/EP4444319A4/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP22903713.0A 2021-12-10 2022-12-09 Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen Pending EP4444319A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141057554 2021-12-10
PCT/IB2022/061996 WO2023105482A1 (en) 2021-12-10 2022-12-09 Citric acid cycle and lactate transport inhibitors for prevention and/or treatment of skin disorders

Publications (2)

Publication Number Publication Date
EP4444319A1 EP4444319A1 (de) 2024-10-16
EP4444319A4 true EP4444319A4 (de) 2025-12-03

Family

ID=86729793

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22903713.0A Pending EP4444319A4 (de) 2021-12-10 2022-12-09 Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen

Country Status (2)

Country Link
EP (1) EP4444319A4 (de)
WO (1) WO2023105482A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049554A1 (en) * 2023-08-28 2025-03-06 New York University Hif1a or glut1 inhibition in inflammatory skin diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051405A1 (en) * 2000-12-27 2002-07-04 Nactilus Ab New clinical treatment
CN105287496A (zh) * 2015-10-08 2016-02-03 北京大学第一医院 一种治疗鱼鳞病的药物组合物及其制备方法
WO2016118842A1 (en) * 2015-01-23 2016-07-28 University Of Florida Research Foundation, Inc. Treatment of lupus using metabolic modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003262515A1 (en) * 2002-09-19 2004-04-08 Nieland, John Mr Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
CN103442705B (zh) * 2011-01-11 2015-11-25 巴塞尔大学 用于治疗癌症和免疫抑制的昔洛舍平与线粒体抑制剂的组合
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
AU2012237327B2 (en) * 2011-04-01 2016-10-20 Iasomai Ab New combination comprising N-acetyl-L-cysteine and its use
WO2013138744A1 (en) * 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
CN106309458A (zh) * 2016-07-28 2017-01-11 中南大学湘雅医院 2‑脱氧‑d‑葡萄糖及其在药学上可接受的盐在制备治疗银屑病药物方面的应用
FR3105222B1 (fr) * 2019-12-20 2022-06-03 Nunii Laboratoire Inhibiteur du transporteur MCT7/SLC16A6 pour son utilisation pour la régulation de la pigmentation cutanée et une composition comprenant ledit inhibiteur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051405A1 (en) * 2000-12-27 2002-07-04 Nactilus Ab New clinical treatment
WO2016118842A1 (en) * 2015-01-23 2016-07-28 University Of Florida Research Foundation, Inc. Treatment of lupus using metabolic modulators
CN105287496A (zh) * 2015-10-08 2016-02-03 北京大学第一医院 一种治疗鱼鳞病的药物组合物及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OFMEISTER V ET AL: "Peptide Epitopes derived from tumor stroma-associated antigens CD105 and FAP alpha for cancer immunotherapy", JOURNAL OF INVESTIGATIVE DERMATOLOGY, ELSEVIER, vol. 125, no. 3, Suppl. S, 24 September 2005 (2005-09-24), pages A70, XP008099590, ISSN: 0022-202X *
REDONDO P ET AL: "Topical N-acetylcysteine for lamellar ichthyosis", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 354, no. 9193, 27 November 1999 (1999-11-27), pages 1880, XP004828125, DOI: 10.1016/S0140-6736(99)04245-2 *
XIAOYAN HUANG ET AL: "Membrane-enriched solute carrier family 2 member 1 (SLC2A1/GLUT1) in psoriatic keratinocytes confers sensitivity to 2-deoxy-D-glucose (2-DG) treatment", EXPERIMENTAL DERMATOLOGY, BLACKWELL MUNSGAARD, COPENHAGEN; DK, vol. 28, no. 2, 21 December 2018 (2018-12-21), pages 198 - 201, XP071778658, ISSN: 0906-6705, DOI: 10.1111/EXD.13850 *

Also Published As

Publication number Publication date
WO2023105482A1 (en) 2023-06-15
EP4444319A1 (de) 2024-10-16

Similar Documents

Publication Publication Date Title
EP3672594A4 (de) Kombinationsprodukt aus bcl-2-inhibitor und mdm2-inhibitor und verwendung davon zur prävention und/oder behandlung von krankheiten
EP3900717C0 (de) Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen
EP4272759A4 (de) Mittel zur prävention oder behandlung von entzündlichen erkrankungen und/oder schmerzerkrankungen
EP4185272A4 (de) Behandlung und prävention von erkrankungen im zusammenhang mit atemwegserkrankungen
EP4094754C0 (de) Zusammensetzungen zur behandlung und/oder prävention von proteinaggregationserkrankungen
EP4196127C0 (de) Nicotinamid-mononukleotid-derivate zur behandlung und prävention von sichelzellkrankheit
EP4438048A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen
EP4238567A4 (de) Neuartige behandlung und prävention von erkrankungen im zusammenhang mit sarkopenie
EP4444319A4 (de) Zitronensäurezyklus und lactattransporthemmer zur vorbeugung und/oder behandlung von hauterkrankungen
EP4404939A4 (de) Hygromycin a zur behandlung von krankheiten und infektionen
EP4403182A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4017496C0 (de) Formulierungen zur vorbeugung und/oder behandlung von peripherer neuropathie und deren assoziierten erkrankungen
EP4119158A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4119160A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4183416A4 (de) Mittel zur prävention oder behandlung von muskelerkrankungen
EP4415737A4 (de) Zusammensetzungen und verfahren zur behandlung von hauterkrankungen
EP4499608A4 (de) Indolizinderivate zur behandlung von trpm3-vermittelten erkrankungen
EP4351618A4 (de) Trem-2/dap-12-hemmer zur behandlung von lungenerkrankungen und -verletzungen und kombinationen davon
EP4440567A4 (de) Therapeutische targets und mittel zur behandlung von posttraumatischen stresserkrankungen
EP4461296A4 (de) Pharmazeutische zusammensetzung zur prävention und/oder behandlung von herzinsuffizienz
EP4401738A4 (de) Arzneimittel zur prävention und/oder behandlung des trockenen auges
EP4267163A4 (de) Zusammensetzungen zur behandlung von hauterkrankungen
EP3534924A4 (de) Zusammensetzung zur vorbeugung und/oder behandlung von herz-kreislauf-erkrankungen
EP4378478A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4355320A4 (de) Organonitro- und sulfoxyalkylorganonitroverbindungen zur verwendung bei der behandlung von medizinischen erkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031700400

Ipc: A61K0031194000

A4 Supplementary search report drawn up and despatched

Effective date: 20251104

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/194 20060101AFI20251029BHEP

Ipc: A61K 31/7004 20060101ALI20251029BHEP

Ipc: A61K 31/198 20060101ALI20251029BHEP

Ipc: A61K 31/336 20060101ALI20251029BHEP

Ipc: A61K 31/475 20060101ALI20251029BHEP

Ipc: A61K 31/4995 20060101ALI20251029BHEP

Ipc: A61K 31/548 20060101ALI20251029BHEP

Ipc: A61P 17/00 20060101ALI20251029BHEP

Ipc: A61P 17/06 20060101ALI20251029BHEP

Ipc: A61P 17/14 20060101ALI20251029BHEP

Ipc: C12Q 1/6869 20180101ALI20251029BHEP

Ipc: C12Q 1/6883 20180101ALI20251029BHEP

Ipc: A61K 31/404 20060101ALI20251029BHEP

Ipc: A61K 31/437 20060101ALI20251029BHEP

Ipc: A61K 31/519 20060101ALI20251029BHEP